Lariat-Cap mRNA Structure for Intracellular Stability and Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
mRNA has lower structural stability than DNA, leading to challenges in industrial use, particularly in mRNA vaccines where high doses are required due to short half-life, causing instability and various side effects.
Innovation Solution
A lariat-cap structure is introduced at the 5' end of mRNA using a ribozyme, enhancing intracellular stability and biosynthesis by forming a lariat-cap structure, which includes a sequence for lariat-cap formation and optionally an internal ribosome entry site (IRES), improving stability and protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If mRNA is used for vaccines, then protein expression can be achieved without nuclear entry, but intracellular stability is poor leading to short half-life
Solution Approach 1:
The patent modifies the chemical structure of mRNA by introducing a lariat-cap structure at the 5' end, which changes the structural parameters of the molecule. This structural modification enhances intracellular stability and extends half-life while maintaining protein expression capability, directly resolving the contradiction between ease of operation and stability.
2Productivity
If high dose of mRNA is administered to compensate for short half-life, then sufficient protein expression is achieved, but side effects increase
Solution Approach 1:
By changing the structural parameters of mRNA through lariat-cap formation, the patent extends half-life and improves intracellular stability. This allows achieving sufficient protein expression at lower doses, thereby reducing side effects while maintaining productivity.
3Ease of manufacture
If conventional mRNA is used, then rapid vaccine production is possible, but structural stability is insufficient for industrial use
Solution Approach 1:
The patent introduces a lariat-cap structure that modifies the structural parameters of mRNA without complicating the manufacturing process. The modified mRNA maintains rapid production capability while achieving sufficient structural stability for industrial use, resolving the contradiction between ease of manufacture and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lariat-cap structure significantly increases mRNA stability, allowing for reduced dosage and enhanced protein expression, reducing side effects and production costs while maintaining effective protein synthesis.
Implementation Method 1
A lariat-cap structure is introduced at the 5' end of mRNA using a ribozyme, enhancing intracellular stability and biosynthesis by forming a lariat-cap structure
Data Source
AI summary
Unlike DNA, mRNA has the advantage of enabling transient expression of a desired protein directly in the cytoplasm without having to enter the nucleus, and thus attempts to use mRNA vaccines are actively underway. However, mRNA has lower structural stability than DNA, and thus has limitations with respect to industrial application. Therefore, the present invention relates to a technology for remarkably improving intracellular stability and biogenesis of mRNA. An mRNA stabilization method and an mRNA stabilization composition, of the present invention, have the excellent effects of enhancing target nucleic acid stabilization and target protein expression in mRNA vaccines and the like, and thus are expected to be widely used in the health/medical field.